Lilly, Acrux receive FDA approval for Axiron
The companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year in the United States.
The companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year in the United States.
The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
Pharmaceutical firms led by Eli Lilly are trying to eliminate a government panel aimed at controlling Medicare spending seven months after they supported the health-care overhaul that created it.
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
Merck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
Eli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s attempt to add diagnostics to its product portfolio.
Moody’s Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent expirations the drugmaker faces in coming years.
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.
The Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions, which could mean another $500 million in annual sales for Lilly, an analyst estimates.
Without an appeal, generic drugs are now poised to wipe away most of Lilly’s $750 million in annual U.S. revenue from Gemzar.
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
Eli Lilly and Co., under pressure to gain new products after setbacks this month with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc.
CEO John Lechleiter claims Eli Lilly and Co. isn’t interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
Wall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
The Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
Eli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage study, the second setback for a Lilly diabetes drug candidate in two days.
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
Indianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150 million plan to expand it.
Eli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.